Literature DB >> 15147460

Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria.

T Fangerau1, S Schimrigk, M Haupts, M Kaeder, G Ahle, N Brune, K Klinkenberg, S Kotterba, M Möhring, E Sindern.   

Abstract

OBJECTIVES: A confident and accurate diagnosis of multiple sclerosis (MS) is important, but a specific diagnostic test for the disease does not exist. The traditional diagnostic criteria of Poser et al. were published in 1983, and recently, McDonald et al. recommended new criteria for the diagnosis of MS. PATIENTS AND METHODS: In this study these two diagnostic schemes were compared by prospectively applying both of them to 76 patients with clinical features suggesting a new diagnosis of MS.
RESULTS: Using the Poser criteria, 29 patients (38%) were classified as clinically definite and 35 patients (46%) as laboratory definite MS. According to the new McDonald criteria, MS was diagnosed in 39 (52%) patients, 37 patients (48%) had 'possible MS'. All patients with a clinically definite MS with the Poser criteria were also given the diagnosis of MS as recommended by McDonald et al. Of those 35 patients with laboratory definite MS according to Poser et al., four patients could be classified as having MS with the McDonald criteria, 89% of them had 'possible MS'. Conversely, 75% of the 39 patients, who fulfilled the new McDonald criteria for MS were assigned to the category of clinically definite MS according to the Poser criteria, and 83% of the patients with a 'possible MS' using the McDonald criteria, had a laboratory definite MS with the Poser criteria.
CONCLUSION: MS according to the McDonald criteria was diagnosed more often than 'clinically definite MS' according to Poser et al., but combining the categories of clinically and laboratory definite MS, the diagnosis of MS could clearly be established more frequently using the Poser criteria. Copyright Blackwell Munksgaard 2003

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147460     DOI: 10.1111/j.1600-0404.2004.00246.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

Review 1.  Diagnosis and treatment of multiple sclerosis.

Authors:  T J Murray
Journal:  BMJ       Date:  2006-03-04

Review 2.  Clinically Isolated Syndromes: Clinical Characteristics, Differential Diagnosis, and Management.

Authors:  Hüsnü Efendi
Journal:  Noro Psikiyatr Ars       Date:  2015-12-01       Impact factor: 1.339

3.  Expression Profile of Selected MicroRNAs in the Peripheral Blood of Multiple Sclerosis Patients: a Multivariate Statistical Analysis with ROC Curve to Find New Biomarkers for Fingolimod.

Authors:  Mohammad Mahdi Eftekharian; Alireza Komaki; Mehrdokht Mazdeh; Shahram Arsang-Jang; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2019-03-21       Impact factor: 3.444

Review 4.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 5.  The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History.

Authors:  Luis Octavio Tierradentro-García; Juan Sebastián Botero-Meneses; Claudia Talero-Gutiérrez
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-05-10

6.  Comparison of The Expression of miR-326 between Interferon beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis.

Authors:  Mahtab Fattahi; Nahid Eskandari; Fattah Sotoodehnejadnematalahi; Vahid Shaygannejad; Mohammad Kazemi
Journal:  Cell J       Date:  2019-09-08       Impact factor: 2.479

7.  Preference-based Health status in a German outpatient cohort with multiple sclerosis.

Authors:  Jens Peter Reese; Gabriele Wienemann; Axel John; Alexandra Linnemann; Monika Balzer-Geldsetzer; Ulrich Otto Mueller; Christian Eienbröker; Björn Tackenberg; Richard Dodel
Journal:  Health Qual Life Outcomes       Date:  2013-10-03       Impact factor: 3.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.